

# Patrick Marcellin

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1892611/patrick-marcellin-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29  
papers

5,111  
citations

21  
h-index

30  
g-index

30  
ext. papers

6,030  
ext. citations

11.4  
avg, IF

5.26  
L-index

#	Paper	IF	Citations
29	Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life. <i>Liver International</i> , <b>2021</b> , 41, 1509-1517	7.9	8
28	New therapies for hepatitis delta virus infection. <i>Liver International</i> , <b>2021</b> , 41 Suppl 1, 30-37	7.9	5
27	Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 964-973 <sup>3,4</sup>		3
26	Future treatments for hepatitis delta virus infection. <i>Liver International</i> , <b>2020</b> , 40 Suppl 1, 54-60	7.9	18
25	Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. <i>Liver International</i> , <b>2019</b> , 39, 1868-1875	7.9	51
24	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. <i>BMC Infectious Diseases</i> , <b>2019</b> , 19, 300	4	2
23	Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?. <i>Liver International</i> , <b>2018</b> , 38 Suppl 1, 7-13	7.9	91
22	Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. <i>Liver International</i> , <b>2018</b> , 38 Suppl 1, 2-6	7.9	207
21	Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1087-1094.e2	6.9	12
20	Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 39-47	13.4	80
19	Combination of Tenofovir Disoproxil Fumarate and Peginterferon $\alpha$ 2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , <b>2016</b> , 150, 134-144.e10	13.3	219
18	Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. <i>Liver International</i> , <b>2016</b> , 36 Suppl 1, 47-57	7.9	174
17	Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). <i>Journal of Hepatology</i> , <b>2016</b> , 64, 1011-1019	13.4	61
16	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2016</b> , 1, 196-206	18.8	259
15	HBSAg quantification to optimize treatment monitoring in chronic hepatitis B patients. <i>Liver International</i> , <b>2015</b> , 35 Suppl 1, 82-90	7.9	49
14	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 41-7 <sup>13,4</sup>		54
13	Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. <i>Cancer</i> , <b>2015</b> , 121, 3631-8	6.4	125

12	Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 1457-64	4	196
11	Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 296-302	3.3	2
10	Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. <i>Gastroenterology</i> , <b>2014</b> , 147, 132-142.e4	13.3	207
9	HBsAg quantification: useful for monitoring natural history and treatment outcome. <i>Liver International</i> , <b>2014</b> , 34 Suppl 1, 97-107	7.9	79
8	Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. <i>Lancet, The</i> , <b>2013</b> , 381, 468-75	40	1128
7	Update on the Role of Quantitative HBsAg and HBeAg Monitoring during Peginterferon Therapy. <i>Current Hepatitis Reports</i> , <b>2012</b> , 11, 75-81		
6	Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B. <i>Liver International</i> , <b>2011</b> , 31 Suppl 1, 122-8	7.9	27
5	Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. <i>Liver International</i> , <b>2011</b> , 31, 516-24	7.9	55
4	Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 2442-55	59.2	897
3	Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. <i>Hepatology</i> , <b>2006</b> , 44, 728-35	11.2	174
2	Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 1206-17	59.2	904
1	Anti-pre-S responses and viral clearance in chronic hepatitis B virus infection. <i>Hepatology</i> , <b>1992</b> , 15, 26-31	11.2	24